Scientists reprogram Patient's own cells to hunt blood cancer

NCT ID NCT00586391

Summary

This is an early-stage safety study testing a new type of treatment for patients whose B-cell lymphoma or leukemia has returned or not responded to standard therapies. Doctors take a patient's own immune cells (T cells), genetically modify them in a lab to better recognize and attack cancer cells, and then infuse them back into the patient. The main goals are to find a safe dose, see how long the modified cells last, and check for any side effects.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Houston Methodist Hospital

    Houston, Texas, 77030, United States

  • Texas Children's Hospital

    Houston, Texas, 77030, United States

Conditions

Explore the condition pages connected to this study.